Molecular Mechanisms of Tumor Angiogenesis and Tumor Progression

The formation of new blood vessels (angiogenesis) is crucial for the growth and persistence of primary solid tumors and their metastases. Furthermore, angiogenesis is also required for metastatic dissemination, since an increase in vascular density will allow easier access of tumor cells to the circulation. Induction of angiogenesis precedes the formation of malignant tumors, and increased vascularization seems to correlate with the invasive properties of tumors and thus with the malignant tumor phenotype. In the last few years, the discovery and characterization of tumor-derived angiogenesis modulators greatly contributed to our understanding of how tumors regulate angiogenesis. However, although angiogenesis appears to be a rate-limiting event in tumor growth and metastatic dissemination, a direct connection between the induction of angiogenesis and the progression to tumor malignancy is less well understood. In this review, we discuss the most recent observations concerning the modulation of angiogenesis and their implications in tumor progression, as well as their potential impact on cancer therapy.

[1]  A. Harris,et al.  Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[2]  J. Folkman,et al.  Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[3]  G. Christofori,et al.  Novel forms of acidic fibroblast growth factor-1 are constitutively exported by β tumor cell lines independent from conventional secretion and apoptosis , 2004, Angiogenesis.

[4]  G. Yancopoulos,et al.  Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. , 1999, Genes & development.

[5]  T. L. Moser,et al.  Angiostatin binds ATP synthase on the surface of human endothelial cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[6]  R. D'Amato,et al.  Inhibition of angiogenesis in vivo by interleukin 12. , 1995, Journal of the National Cancer Institute.

[7]  Robert S. Kerbel,et al.  Establishing a Link between Oncogenes and Tumor Angiogenesis , 1998, Molecular medicine.

[8]  K. Alitalo,et al.  Signaling angiogenesis and lymphangiogenesis. , 1998, Current opinion in cell biology.

[9]  Harold E. Dvorak,et al.  Angiogenesis: a Dynamic Balance of Stimulators and Inhibitors , 1997, Thrombosis and Haemostasis.

[10]  B. Teicher,et al.  Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. , 1992, Cancer research.

[11]  E. Keshet,et al.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.

[12]  D. Hanahan,et al.  Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma , 1991, Cell.

[13]  I Que,et al.  Endostatin inhibits VEGF‐induced endothelial cell migration and tumor growth independently of zinc binding , 1999, The EMBO journal.

[14]  B. Zetter,et al.  Angiogenesis and tumor metastasis. , 1998, Annual review of medicine.

[15]  G. Christofori The implications of angiogenesis on tumor invasiveness. , 1998, Angiogenesis.

[16]  J. Folkman,et al.  gro-beta, a -C-X-C- chemokine, is an angiogenesis inhibitor that suppresses the growth of Lewis lung carcinoma in mice , 1995, The Journal of experimental medicine.

[17]  N. Ferrara,et al.  OncogenicrasFails to Restore anin VivoTumorigenic Phenotype in Embryonic Stem Cells Lacking Vascular Endothelial Growth Factor (VEGF) , 1999 .

[18]  Mark D. Johnson,et al.  Inhibition of angiogenesis by tissue inhibitor of metalloproteinase , 1994, Journal of cellular physiology.

[19]  Napoleone Ferrara,et al.  Clinical applications of angiogenic growth factors and their inhibitors , 1999, Nature Medicine.

[20]  G. Martin,et al.  The Role of Basement Membranes in Vascular Development , 1990, Annals of the New York Academy of Sciences.

[21]  D. Hanahan,et al.  Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Thomas N. Sato,et al.  Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. , 1997, Science.

[23]  D. Hanahan,et al.  Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. , 1999, Cancer research.

[24]  E. Borden,et al.  Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. , 1987, Cancer research.

[25]  S. Fox,et al.  Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy , 2004, Investigational New Drugs.

[26]  Lars Holmgren,et al.  Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.

[27]  J. Folkman,et al.  Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[28]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[29]  M. Matsumoto,et al.  Hypoxia-mediated induction of acidic/basic fibroblast growth factor and platelet-derived growth factor in mononuclear phagocytes stimulates growth of hypoxic endothelial cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[30]  A. Logan,et al.  Angiogenesis , 1993, The Lancet.

[31]  H. Granger,et al.  Inhibitory effect of full-length human endostatin on in vitro angiogenesis. , 1999, Biochemical and biophysical research communications.

[32]  David W. Dawson,et al.  CD36 Mediates the In Vitro Inhibitory Effects of Thrombospondin-1 on Endothelial Cells , 1997, The Journal of cell biology.

[33]  N. Ferrara,et al.  Oncogenic ras fails to restore an in vivo tumorigenic phenotype in embryonic stem cells lacking vascular endothelial growth factor (VEGF). , 1999, Biochemical and biophysical research communications.

[34]  Mihaela Skobe,et al.  Halting angiogenesis suppresses carcinoma cell invasion , 1997, Nature Medicine.

[35]  G. Christofori,et al.  Fibroblast Growth Factors in Tumor Progression and Angiogenesis , 1999 .

[36]  G. Christofori The implications of angiogenesison tumor invasiveness , 2004, Angiogenesis.

[37]  N. Bouck,et al.  Thrombospondin as an Inhibitor of Angiogenesis , 1999 .

[38]  R. Xavier,et al.  Tumor Induction of VEGF Promoter Activity in Stromal Cells , 1998, Cell.

[39]  E. Sage,et al.  Angiostatin Diminishes Activation of the Mitogen-Activated Protein Kinases ERK-1 and ERK-2 in Human Dermal Microvascular Endothelial Cells , 1999, Journal of Vascular Research.

[40]  P. Campochiaro,et al.  Basic fibroblast growth factor is neither necessary nor sufficient for the development of retinal neovascularization. , 1998, The American journal of pathology.

[41]  A. Ullrich,et al.  Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. , 1993, Cancer research.

[42]  J. Folkman,et al.  Angiostatin induces and sustains dormancy of human primary tumors in mice , 1996, Nature Medicine.

[43]  E. Lander,et al.  Tumor suppressor loci on mouse chromosomes 9 and 16 are lost at distinct stages of tumorigenesis in a transgenic model of islet cell carcinoma. , 1995, Cancer research.

[44]  N. Ferrara,et al.  The biology of vascular endothelial growth factor. , 1997, Endocrine reviews.

[45]  T. Danielsen,et al.  Hypoxia-induced angiogenesis and vascular endothelial growth factor secretion in human melanoma. , 1998, British Journal of Cancer.

[46]  D. Hanahan,et al.  Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. , 1999, Science.

[47]  J. Shiloach,et al.  Zinc-binding of endostatin is essential for its antiangiogenic activity. , 1998, Biochemical and biophysical research communications.

[48]  Thomas N. Sato,et al.  Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation , 1995, Nature.

[49]  W. Stetler-Stevenson,et al.  Tissue inhibitor of metalloproteinases‐2 inhibits bFGF‐induced human microvascular endothelial cell proliferation , 1993, Journal of cellular physiology.

[50]  Y. Cao,et al.  Endogenous angiogenesis inhibitors: angiostatin, endostatin, and other proteolytic fragments. , 1998, Progress in molecular and subcellular biology.

[51]  M. Dewhirst,et al.  Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[52]  R. Kerbel,et al.  Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[53]  R. Kerbel A cancer therapy resistant to resistance , 1997, Nature.

[54]  S. Tsang,et al.  Neuronal defects and delayed wound healing in mice lacking fibroblast growth factor 2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[55]  S. Mandriota,et al.  Regulation of vascular endothelial growth factor receptor-2 (Flk-1) expression in vascular endothelial cells. , 1998, Experimental cell research.

[56]  R. Timpl,et al.  Angiogenesis inhibitor endostatin is a distinct component of elastic fibers in vessel walls , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[57]  M. Stack,et al.  Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation. , 1999, The Biochemical journal.

[58]  D. Cheresh,et al.  Integrins and cancer. , 1996, Current opinion in cell biology.

[59]  L. Ellis,et al.  Down-regulation of Vascular Endothelial Growth Factor in a Human Colon Carcinoma Cell Line Transfected with an Antisense Expression Vector Specific for c-src * , 1998, The Journal of Biological Chemistry.

[60]  K. Dameron,et al.  The p53 tumor suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin. , 1994, Cold Spring Harbor symposia on quantitative biology.

[61]  Pamela F. Jones,et al.  Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, during Embryonic Angiogenesis , 1996, Cell.

[62]  Thomas Boehm,et al.  Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance , 1997, Nature.

[63]  A. Aguzzi,et al.  Early induction of angiogenetic signals in gliomas of GFAP-v-src transgenic mice. , 1999, The American journal of pathology.

[64]  D. Mukhopadhyay,et al.  The von Hippel-Lindau Gene Product Inhibits Vascular Permeability Factor/Vascular Endothelial Growth Factor Expression in Renal Cell Carcinoma by Blocking Protein Kinase C Pathways* , 1997, The Journal of Biological Chemistry.

[65]  V. Sukhatme,et al.  Endostatin Induces Endothelial Cell Apoptosis* , 1999, The Journal of Biological Chemistry.

[66]  W. Risau,et al.  Mechanisms of angiogenesis , 1997, Nature.

[67]  N. Bouck,et al.  Multiple forms of angiostatin induce apoptosis in endothelial cells. , 1998, Blood.

[68]  R. Kerbel,et al.  Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. , 1995, Cancer research.

[69]  D. Cheresh,et al.  The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. , 1999, The Journal of clinical investigation.

[70]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[71]  D. Benezra Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. , 1997, Investigative ophthalmology & visual science.

[72]  N. Bouck,et al.  How tumors become angiogenic. , 1996, Advances in cancer research.

[73]  M. Ittmann,et al.  Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma. , 1999, Human pathology.

[74]  A. Friedl,et al.  Endostatin binds to blood vessels in situ independent of heparan sulfate and does not compete for fibroblast growth factor-2 binding. , 1999, The American journal of pathology.

[75]  J. Williams,et al.  Heparin-binding fragments of fibronectin are potent inhibitors of endothelial cell growth. , 1985, The American journal of pathology.

[76]  J. Folkman Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[77]  Y. Kakeji,et al.  Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents , 2004, Investigational New Drugs.

[78]  Daniel B. Rifkin,et al.  Fibroblast Growth Factor-2 (FGF-2) Induces Vascular Endothelial Growth Factor (VEGF) Expression in the Endothelial Cells of Forming Capillaries: An Autocrine Mechanism Contributing to Angiogenesis , 1998, The Journal of cell biology.

[79]  D. Hanahan,et al.  Angiogenesis and apoptosis are cellular parameters of neoplastic progression in transgenic mouse models of tumorigenesis. , 1998, The International journal of developmental biology.

[80]  D. Taub,et al.  Human Interferon-inducible Protein 10 Is a Potent Inhibitor of Angiogenesis in Vivo , 1995 .

[81]  R. Timpl,et al.  Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin , 1999, The EMBO journal.